Zomedica Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA98980M1095
USD
0.11
0 (-0.37%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Rigel Pharmaceuticals, Inc.
Verrica Pharmaceuticals, Inc.
Zomedica Corp.
Omeros Corp.
Fusion Pharmaceuticals, Inc.
Gossamer Bio, Inc.
Emergent BioSolutions, Inc.
Sagimet Biosciences, Inc.
Merrimack Pharmaceuticals, Inc.
Tenaya Therapeutics, Inc.
PolyPid Ltd.

Why is Zomedica Corp. ?

Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Zomedica Corp. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Icon
No Data Found
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
101.27%
EBIT Growth (5y)
-21.49%
EBIT to Interest (avg)
-27.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.48
Sales to Capital Employed (avg)
0.17
Tax Ratio
0.44%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.10%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.08
EV to EBIT
-2.51
EV to EBITDA
-3.49
EV to Capital Employed
1.14
EV to Sales
2.24
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-45.37%
ROE (Latest)
-22.55%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

24What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -13.15 MM

ROCE(HY)

Highest at -16.29%

OPERATING PROFIT(Q)

Highest at USD -2.24 MM

PRE-TAX PROFIT(Q)

Highest at USD -3.74 MM

NET SALES(Q)

At USD 9.51 MM has Grown at 36.59%

OPERATING PROFIT MARGIN(Q)

Highest at -23.55 %

NET PROFIT(Q)

Highest at USD -3.77 MM

EPS(Q)

Highest at USD -0

-3What is not working for the Company
RAW MATERIAL COST(Y)

Grown by 5.29% (YoY

CASH AND EQV(HY)

Lowest at USD 91.64 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 8.25 times

Here's what is working for Zomedica Corp.

Operating Cash Flow
Highest at USD -13.15 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Operating Profit
Highest at USD -2.24 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Operating Profit trend is quite positive

Operating Profit (USD MM)

Pre-Tax Profit
Highest at USD -3.74 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Sales
At USD 9.51 MM has Grown at 36.59%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Operating Profit Margin
Highest at -23.55 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Net Profit
Highest at USD -3.77 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD -0
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Here's what is not working for Zomedica Corp.

Cash and Eqv
Lowest at USD 91.64 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio
Lowest at 8.25 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost
Grown by 5.29% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales